Showing results (1-10 of 42) with videos related to
Sort By:
Pageof 5
Cancers|October 2, 2019
PTEN and Gynecological CancersCamilla Nero, Francesca Ciccarone, Antonella Pietragalla, et al.Recenti Progressi in Medicina|June 15, 2021
[Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.]Romano Danesi, Chiara Cremolini, Francesca Ciccarone, et al.Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Integration of PARP-inhibitors in ovarian cancer therapyAntonella Pietragalla, Francesca Ciccarone, Camilla Nero, et al.Frontiers in Oncology|September 20, 2021
Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk AssessmentCamilla Nero, Francesca Ciccarone, Antonella Pietragalla, et al.Cancers|April 30, 2021
Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical DataSimona Duranti, Antonella Pietragalla, Gennaro Daniele, et al.European Journal of Obstetrics, Gynecology, and Reproductive Biology|May 14, 2021
Disseminated peritoneal leiomyomatosis and malignant transformation: A case series in a single referral centerAndrea Rosati, Virginia Vargiu, Giuseppe Angelico, et al.Expert Opinion on Investigational Drugs|January 11, 2021
Oregovomab: an investigational agent for the treatment of advanced ovarian cancerAntonella Pietragalla, Simona Duranti, Gennaro Daniele, et al.Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Immunotherapy in gynecological cancersDomenica Lorusso, Valentina Ceni, Gennaro Daniele, et al.Cancer Treatment Reviews|October 17, 2020
Newly diagnosed ovarian cancer: Which first-line treatment?Domenica Lorusso, Valentina Ceni, Gennaro Daniele, et al.Cancers|April 3, 2021
Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point InhibitorsCamilla Nero, Francesca Ciccarone, Antonella Pietragalla, et al.Pageof 5